MétaCan
Menu
Back to cohort
Record W3102146372 · doi:10.1136/bmjopen-2020-040110

Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial

2020· article· en· W3102146372 on OpenAlexaff
Mikaëla Smit, Annalisa Marinosci, G. Nicoletti, Thomas Perneger, Silvio Ragozzino, Diego O. Andrey, Marcel Stoeckle, Frédérique Jacquérioz, Dan Lebowitz, Thomas Agoritsas, Benjamin Meyer, Hervé Spechbach, Julien Salamun, Moritz Back, Carla Schaubhut, Simon Fuchs, Laurent A. Décosterd, Manuel Battegay, Idris Guessous, François Chappuis, Laurent Kaiser, Niklaus Daniel Labhardt, Alexandra Calmy

Bibliographic record

VenueBMJ Open · 2020
Typearticle
Languageen
FieldMedicine
TopicSARS-CoV-2 detection and testing
Canadian institutionsMcMaster UniversityImpact
FundersFondation privée des Hôpitaux universitaires de Genève
KeywordsMedicineLopinavirAsymptomaticIncidence (geometry)Pre-exposure prophylaxisRitonavirClinical endpointPost-exposure prophylaxisIntention-to-treat analysisRandomized controlled trialCluster (spacecraft)Internal medicineTrial registrationChemoprophylaxisPediatricsCoronavirus disease 2019 (COVID-19)Viral loadImmunologyHuman immunodeficiency virus (HIV)Antiretroviral therapyMen who have sex with menDisease

Abstract

fetched live from OpenAlex

INTRODUCTION: Lopinavir/ritonavir (LPV/r) has been proposed as repurposed drugs for pre-exposure and postexposure prophylaxis as well as therapy of COVID-19. Coronavirus postexposure prophylaxis (COPEP) trial aims at assessing their efficacy as postexposure ring-prophylaxis among adults exposed to SARS-CoV-2. METHODS AND ANALYSIS: COPEP is a two-arm open-label cluster-randomised trial conducted in three cantons of Switzerland. Asymptomatic contacts (≥16 years) of individuals diagnosed with COVID-19 will be randomised (2:1) to either LPV/r (400 mg/100 mg two times per day) for 5 days, or a standard of care arm (no treatment). Asymptomatic individuals may be either SARS-CoV-2 positive or negative. Contacts living in the single household will form a cluster and will be randomised into the same arm. All participants will be followed-up for 21 days and undergo daily monitoring for COVID-19 symptoms. The primary endpoint is 21-day incidence of laboratory-confirmed COVID-19 with ≥1 compatible symptom, analysed in an intention-to-treat (ITT) analysis. The secondary endpoints include the 21-day incidence of COVID-19 as well as SARS-CoV-2 infection in a modified ITT analysis, excluding participants who had a positive SARS-CoV-2 RT-PCR from oropharyngeal swab and/or a positive SARS-CoV-2 IgG serology at baseline. Assuming a 21-day incidence for COVID-19 of 20% among contacts without postexposure chemoprophylaxis, to detect a relative risk reduction of 60% (ie, translating in an absolute reduction from 20% to 8%), with a power of 80%, an alpha of 5%. Accounting for design effect of cluster design of circa 1.1, we plan to enrol 200 participants to the LPV/r arm and 100 to the standard of care arm, 300 participants in total. ETHICS AND DISSEMINATION: Ethics approval has been granted by the Commission Cantonale d'Ethique de la Recherche, Ethikkommission Nordwest- und Zentralschweiz and Comitato Etico Cantonale (ref 2020-00864) and Swissmedic (2020DR3056). Results from this trial will be disseminated via journal articles and presentations at national and international conferences. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov Registry (NCT04364022); Swiss National Clinical Trial Portal Registry (SNCTP 000003732). REGISTERED REPORT IDENTIFIER: CCER 2020-0864.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.019
metaresearch head score (Gemma)0.016
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.041
Threshold uncertainty score0.139

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0190.016
Meta-epidemiology (narrow)0.0060.002
Meta-epidemiology (broad)0.0080.005
Bibliometrics0.0010.002
Science and technology studies0.0020.004
Scholarly communication0.0040.003
Open science0.0030.002
Research integrity0.0060.006
Insufficient payload (model declined to judge)0.0410.009

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.186
GPT teacher head0.451
Teacher spread0.266 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations7
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueBMJ OpenSame topicSARS-CoV-2 detection and testingFrench-language works237,207